MFIMFI
ANIP icon

Mesirow Financial Investment Management - Fixed Income’s ANI Pharmaceuticals ANIP Stock Holding History

Mesirow Financial Investment Management - Fixed Income’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6,895
Closed -$341K – 116
2017
Q1 		$341K Buy
6,895
+3,430
+99% +$193K 0.02% 138
2016
Q4 		$210K Sell
3,465
-305
-8% -$18.6K 0.01% 225
2016
Q3 		$250K Buy
+3,770
New +$236K 0.01% 211

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mesirow Financial Investment Management - Fixed Income's ANIP Position: Q2 2017 in Review

Mesirow Financial Investment Management - Fixed Income sold out of ANI Pharmaceuticals (ANIP) in Q2 2017, closing a stake of 6,895 shares — an estimated $341K sold.

Mesirow Financial Investment Management - Fixed Income first reported a position in ANIP in Q3 2016 and held it in 3 quarters. The position peaked at $341K in Q1 2017. 151 funds tracked by Wall St. Rank hold ANIP as of Q2 2017.

  • Mesirow Financial Investment Management - Fixed Income reported no remaining ANI Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Mesirow Financial Investment Management - Fixed Income sold 6,895 ANI Pharmaceuticals shares in Q2 2017, an estimated $341K.
  • Mesirow Financial Investment Management - Fixed Income first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Mesirow Financial Investment Management - Fixed Income's ANI Pharmaceuticals position peaked at $341K in Q1 2017.
  • 151 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2017.

Based on Mesirow Financial Investment Management - Fixed Income's 13F filing for Q2 2017, filed 1 Aug 2017.